奥妥珠单抗联合苯丁酸氮芥治疗慢性淋巴细胞白血病的相对剂量强度：一项意大利多中心研究 - Suppr

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study.

作者信息

Fresa Alberto, Autore Francesco, Piciocchi Alfonso, Catania Gioacchino, Visentin Andrea, Tomasso Annamaria, Moretti Marina, Vitale Candida, Chiarenza Annalisa, Morelli Francesca, Sportoletti Paolo, Marasca Roberto, Sapienza Giuseppe, Cuccaro Annarosa, Murru Roberta, Sanna Alessandro, Patti Caterina, Angeletti Ilaria, Coscia Marta, Trentin Livio, Pietrasanta Daniela, Innocenti Idanna, Laurenti Luca

机构信息

Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

出版信息

Blood Adv. 2022 Jul 12;6(13):3875-3878. doi: 10.1182/bloodadvances.2022006964.

DOI:10.1182/bloodadvances.2022006964

PMID:35789375

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9278285/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/607e/9278285/ff2442be55a2/advancesADV2022006964f1.jpg

相似文献

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study.

Blood Adv. 2022 Jul 12;6(13):3875-3878. doi: 10.1182/bloodadvances.2022006964.

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3.

A cross-trial comparison of single-agent ibrutinib chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Haematologica. 2020 Apr;105(4):e164-e168. doi: 10.3324/haematol.2019.223743. Epub 2019 Aug 14.

Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.

Intern Med J. 2017 Jul;47 Suppl 4:5-10. doi: 10.1111/imj.13493.

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.

Clin Interv Aging. 2015 Jun 12;10:951-61. doi: 10.2147/CIA.S69278. eCollection 2015.

Obinutuzumab looks impressive in CLL.

Cancer Discov. 2014 Apr;4(4):OF5. doi: 10.1158/2159-8290.CD-NB2014-024. Epub 2014 Feb 13.

Obinutuzumab (Gazyva) for chronic lymphocytic leukemia.

Med Lett Drugs Ther. 2014 Nov 10;56(1455):e114-5.

Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.

Ann Pharmacother. 2014 Oct;48(10):1356-61. doi: 10.1177/1060028014543271. Epub 2014 Jul 18.

Obinutuzumab for chronic lymphocytic leukemia.

Expert Rev Hematol. 2014 Oct;7(5):533-43. doi: 10.1586/17474086.2014.953478. Epub 2014 Aug 28.

Obinutuzumab for the treatment of chronic lymphocytic leukemia.

Drugs Today (Barc). 2014 Jun;50(6):407-19. doi: 10.1358/dot.2014.50.6.2138702.

引用本文的文献

Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases.

Biomedicines. 2024 Dec 20;12(12):2902. doi: 10.3390/biomedicines12122902.

Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.

Neurol Neuroimmunol Neuroinflamm. 2023 May 3;10(4). doi: 10.1212/NXI.0000000000200122. Print 2023 Jul.

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study.

Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022.

本文引用的文献

Treatment Options for Elderly/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review.

J Clin Med. 2021 Oct 30;10(21):5104. doi: 10.3390/jcm10215104.

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Blood Adv. 2021 Dec 28;5(24):5490-5500. doi: 10.1182/bloodadvances.2021004824.

Non-overt disseminated intravascular coagulopathy associated with the first obinutuzumab administration in patients with chronic lymphocytic leukemia.

Hematol Oncol. 2021 Aug;39(3):423-427. doi: 10.1002/hon.2837. Epub 2021 Feb 3.

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.

Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.

Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5.

Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.

Br J Haematol. 2020 Nov;191(3):426-432. doi: 10.1111/bjh.17032. Epub 2020 Aug 10.

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region.

Front Oncol. 2020 Jun 10;10:848. doi: 10.3389/fonc.2020.00848. eCollection 2020.

Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.

Hematol Oncol. 2020 Oct;38(4):509-516. doi: 10.1002/hon.2744. Epub 2020 Jun 1.

Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.

Am J Hematol. 2020 Jun;95(6):604-611. doi: 10.1002/ajh.25766. Epub 2020 Mar 14.

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.

N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献